ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 719

Biomarkers of Pulmonary Hypertension in Patients with Scleroderma: A Case-Control Study

Zsuzsanna H. McMahan1, Florian Schoenhoff2, Jennifer van Eyk3, Fredrick M. Wigley4 and Laura K. Hummers4, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Department of Cardiovascular Surgery, Berne, Switzerland, 3Johns Hopkins University and Cedars Sinai Medical Center, Los Angeles, CA, 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, pulmonary complications and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: The objective of this study was to evaluate for an association between various biomarkers and the presence or absence of pulmonary hypertension (PH) in scleroderma

Methods: Proteomic analysis was used to retrospectively compare growth factor and cytokine levels in 48 patients with scleroderma and PH and 48 patients with scleroderma without clinical or ECHO evidence of PH.  PH was defined as either an mPAP ≥ 25mmHg by right heart catheterization (n = 44) or an RVSP of > 45 mmHg by Echo with strong clinical evidence supporting a diagnosis (n= 4). An additional proteomic analysis was performed on a subset of 24 patients from each group using samples that had been drawn at least 6 months prior to the first sample to determine if changes in candidate biomarker levels were associated with PH. A multiplex proteomic assay was subsequently performed to look at growth factors (bFGF, PIGF, VEGF, HGF, sFLT-1) and cytokine levels (IL 1B, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12 p70, IL-13, TNF-alpha, and INF-gamma) (MesoScale Discovery, Gaithersburg, MD). Univariate and multivariable logistic regression were used to examine the association of growth factor and cytokine levels with the presence of pulmonary hypertension.

Results:

The mean age in the PH group was 66 yrs (range 34-89) compared to 56 (range 27-83) in the non-PH group.  Seventy-three percent (n=35) in the PH group had limited scleroderma compared to 65% (n=31) in the control group. Average disease duration was 17.3 years in the PH group and 12.2 years in the non-PH group.  Differences in gender and scleroderma subtype were not significant between the two groups. We found levels of IL-12 p70 (9.0 vs. 4.0; p=0.04), PlGF (26.7 vs. 21.3, p = 0.01), and sFLT-1(122.1 vs. 99.1, p=0.02) were significantly higher in the 48 patients with PH compared with the 48 without PH at the latest blood sampling time point. When comparing biomarker levels at the earlier time point (17/24 with sample prior to PH diagnosis in the PH group) in the 24 patients with and 24 patients without pulmonary hypertension, sFLT-1 (122.2 vs. 100.5; p= 0.0062; CI -36.87, -6.52), HGF (451.6 vs. 202.1; p =0.003; CI  -403.79,  -95.28), and IL-10 (12.6 vs. 4.4; p= 0.03; CI -15.67, -.85), were significantly higher in the PH group. In a multivariable model adjusted for age, race, disease duration, and ILD, PlGF remained higher among those with PH (OR 1.06, p=0.16) although this was no longer statistically significant. In examining the stability of markers over time, all biomarkers were stable between the two samples except for VEGF (260.8 vs. 546.1; p=0.001) and bFGF (19.8 vs. 11.1; p= 0.01) which showed wide variability in levels between patients and at the 2 time points.  IL-12p70 (-0.24, p = 0.05, CI -0.48, -0.00) and IL-5 (-0.51, p= 0.03, CI -0.952, -0.059) were negatively associated with severity of pulmonary hypertension as measured by mean pulmonary artery pressures (mPAP) among those with PH.

Conclusion: We found that PlGF (and possibly sFLT-1 and IL-12) may be associated with PH in scleroderma. This study confirms prior associations of PlGF with scleroderma vascular disease and suggests that this factor should be further explored as possible biomarkers of development of PH.


Disclosure:

Z. H. McMahan,
None;

F. Schoenhoff,
None;

J. van Eyk,
None;

F. M. Wigley,
None;

L. K. Hummers,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biomarkers-of-pulmonary-hypertension-in-patients-with-scleroderma-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology